Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 35 for:    pralatrexate AND cells

A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03150602
Recruitment Status : Recruiting
First Posted : May 12, 2017
Last Update Posted : May 12, 2017
Sponsor:
Information provided by (Responsible Party):
Taiwan Mundipharma Pharmaceuticals Ltd.

Brief Summary:
This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)

Condition or disease Intervention/treatment Phase
Peripheral T Cell Lymphoma Progression, Disease Drug: Pralatrexate Phase 4

Detailed Description:

Peripheral T-cell lymphomas (PTCL) are a group of aggressive and diverse lymphoproliferative disorders. It is characterized by the presence of malignant mature T-cells or NK cells. There is as yet no consensus regarding standard frontline or relapsed/refractory therapy for PTCL.

A previous phase II study conducted in US showed durable responses of pralatrexate treatment in relapsed or refractory PTCL, irrespective of age, histological subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. This single-arm, multi-center study aims to evaluate the efficacy and safety of pralatrexate monotherapy in prior treatment failure PTCL patients who may undergo HSCT in case of CR or PR, or continue pralatrexate in case of CR, PR or SD.

Primary objective:

  • To evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)

Secondary objectives:

  • To determine the safety of pralatrexate in Asian PTCL patients by,

    • Incidence of adverse events (AEs) and serious adverse events (SAEs) emergent from the treatment
  • To evaluate the efficacy of pralatrexate in Asian PTCL patients after prior treatment failure by,

    • Overall survival (OS), progression-free-survival (PFS), complete response (CR) and partial response (PR) rate, and duration of CR and PR
    • Treatment duration with pralatrexate in the patients without hematopoietic stem cell transplant (HSCT) who achieve CR or PR
    • Percentage of patients who undergo HSCT
    • 1-year OS, 1-year PFS, and 1-year relapse rate after HSCT
    • 2-year OS, 2-year PFS, and 2-year relapse rate after HSCT

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Actual Study Start Date : August 30, 2016
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Pralatrexate treatment
Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
Drug: Pralatrexate
This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
Other Name: Folotyn




Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Up to 35 weeks ]
    Objective response rate (ORR) to pralatrexate treatment in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)


Secondary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Up to 40 weeks ]
    Incidence of adverse events (AE) and serious adverse events (SAE) emergent from the treatment

  2. Overall survival [ Time Frame: Up to 5 years ]
    Duration of overall survival (months)

  3. Progression-free survival [ Time Frame: Up to 5 years ]
    Duration of PFS (months)

  4. Completion response rate [ Time Frame: Up to 5 years ]
    The percentage of CR

  5. Partial response rate [ Time Frame: Up to 5 years ]
    The percentage of PR

  6. Duration of CR and PR [ Time Frame: Up to 5 years ]
    Duration of completion response and partial response (days)

  7. Treatment duration [ Time Frame: Up to 35 weeks ]
    Treatment duration with pralatrexate in the patients without HSCT who achieve CR or PR

  8. Hematopoietic stem cell transplant (HSCT) [ Time Frame: Up to 5 years ]
    Percentage of patients who undergo HSCT

  9. 1-year OS rate after HSCT [ Time Frame: Up to 1 year ]
    1-year overall survival rate after conducting HSCT

  10. 1-year PFS rate after HSCT [ Time Frame: Up to 1 year ]
    1-year progression-free survival rate after conducting HSCT

  11. 1-year relapse rate after HSCT [ Time Frame: Up to 1 year ]
    1-year relapse rate after conducting HSCT

  12. 2-year OS rate after HSCT [ Time Frame: Up to 2 years ]
    2-year overall survival rate after conducting HSCT

  13. 2-year PFS rate after HSCT [ Time Frame: Up to 2 years ]
    2-year progression-free survival rate after conducting HSCT

  14. 2-year relapse rate after HSCT [ Time Frame: Up to 2 years ]
    2-year relapse rate after conducting HSCT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. At least 20 years of age, inclusive
  2. Patients with histologically/cytologically confirmed PTCL using either: NCCN diagnosis criteria, the Revised European American Lymphoma (REAL), and World Health Organization (WHO) disease classification (PTCL histology/cytology subtypes diagnosed by site investigators, PTCL histology/cytology subtypes rechecked by study central pathology lab):

    1. At least 5 patients with Peripheral T-cell lymphoma, NOS
    2. At least 5 patients with Angioimmunoblastic T-cell lymphoma
    3. At least 5 patients with Extranodal NK/T-cell lymphoma, nasal type
    4. Enteropathy-type T-cell lymphoma
    5. Hepatosplenic T-cell lymphoma
    6. Subcutaneous panniculitis-like T-cell lymphoma
    7. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
  3. Patients with documented progressive disease (PD) failed after prior treatment

    1. Patients may not have received an experimental drug as their only prior therapy
    2. Patient has had at least 1 biopsy from initial diagnosis of PTCL or in the relapsed setting to confirm PTCL subtypes
    3. Patient has recovered from the toxic effects of prior therapy
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  5. Adequate hematological, hepatic, and renal function as defined by: absolute neutrophil count (ANC) ≥ 1000/µL, platelet count ≥ 100,000/µL (and ≥ 50,000/µL for any following dose), total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST/ALT < 5 X ULN if documented hepatic involvement with lymphoma), creatinine ≤ 1.5 mg/dL or a calculated creatinine clearance ≥ 50 mL/min.
  6. Women of childbearing potential must agree to practice medically acceptable contraceptive regimen from 30 days prior to study treatment initiation until at least 30 days after the last administration of pralatrexate and must have had a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are postmenopausal for at least 1 year (> 12 months since last menses) or were surgically sterilized do not require this test.
  7. Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.
  8. Patient has provided written informed consent (IC)

Exclusion Criteria:

  1. Patient has following subtypes (histologically/cytologically confirmed) of PTCL

    1. Anaplastic large cell lymphoma, ALK +/-
    2. Patient has: Precursor T/NK neoplasms, with the exception of blastic NK lymphoma
    3. T-cell prolymphocytic leukemia (T-PLL)
    4. T-cell large granular lymphocytic leukemia
    5. Mycosis fungoides and transformed mycosis fungoides
    6. Sézary syndrome
    7. Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis
    8. Patient has: Extranodal NK/T-cell lymphoma, nasal type with local recurrence
  2. Active concurrent malignancy (except for non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years.
  3. Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure guidelines.
  4. Patients with human immunodeficiency virus (HIV)-positive diagnosis and are receiving combination anti-retroviral therapy.
  5. Current or the history of brain metastases or central nervous system (CNS) diseases
  6. Have undergone allogeneic stem cell transplant
  7. Relapsed less than 75 days from time of autologous stem cell transplant
  8. Patients with uncontrolled hypertension, active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment
  9. Had major surgery within 2 weeks of study entry
  10. Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study
  11. Receipt of corticosteroids within 7 days of study treatment, unless patient has been taking a stable dose of no more than 10 mg/day of prednisone for at least 1 month
  12. Use of any investigational drug, biologic modifier, or device within 4 weeks prior to study treatment or planned use during the course of the study
  13. Previous exposure to pralatrexate
  14. Other conditions that investigators consider not suitable for study enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03150602


Contacts
Layout table for location contacts
Contact: Bor-Sheng Ko, PhD 886-23123456 ext 63576 kevinkomd@gmail.com
Contact: Brook Chung, MSc 886-87297521 brook.chung@mundipharma.com.tw

Locations
Layout table for location information
Taiwan
Ntional Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Bor-Sheng Ko, PhD    886-23123456 ext 63576    kevinkomd@gmail.com   
Contact: Brook Chung, MSc    886-87297521    brook.chung@mundipharma.com.tw   
Principal Investigator: Bor-Sheng Ko, PhD         
Sponsors and Collaborators
Taiwan Mundipharma Pharmaceuticals Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Bor-Sheng Ko, PhD National Taiwan University Hospital

Publications:
Society TLL, Peripheral T-Cell Lymphoma Facts, 2014.

Layout table for additonal information
Responsible Party: Taiwan Mundipharma Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT03150602     History of Changes
Other Study ID Numbers: FOT14-TW-401
First Posted: May 12, 2017    Key Record Dates
Last Update Posted: May 12, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Lymphoma
Disease Progression
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Lymphoma, Non-Hodgkin
Aminopterin
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action